Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTaweewun Hunsawongen_US
dc.contributor.authorPanya Sunintaboonen_US
dc.contributor.authorSaradee Wariten_US
dc.contributor.authorButsaya Thaisomboonsuken_US
dc.contributor.authorRichard G. Jarmanen_US
dc.contributor.authorIn Kyu Yoonen_US
dc.contributor.authorSukathida Ubolen_US
dc.contributor.authorStefan Fernandezen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand National Center for Genetic Engineering and Biotechnologyen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.contributor.otherUnited States Armyen_US
dc.identifier.citationPLoS Neglected Tropical Diseases. Vol.9, No.9 (2015)en_US
dc.description.abstract© 2015, Public Library of Science. All Rights Reserved. Dengue viruses (DENVs) are among the most rapidly and efficiently spreading arboviruses. WHO recently estimated that about half of the world’s population is now at risk for DENV infection. There is no specific treatment or vaccine available to treat or prevent DENV infections. Here, we report the development of a novel dengue nanovaccine (DNV) composed of UV-inactivated DENV-2 (UVI-DENV) and Mycobacterium bovis Bacillus Calmette-Guerin cell wall components (BCG-CWCs) loaded into chitosan nanoparticles (CS-NPs). CS-NPs were prepared by an emulsion polymerization method prior to loading of the BCG-CWCs and UVI-DENV components. Using a scanning electron microscope and a zetasizer, DNV was determined to be of spherical shape with a diameter of 372.0 ± 11.2 nm in average and cationic surface properties. The loading efficacies of BCG-CWCs and UVI-DENV into the CS-NPs and BCG-CS-NPs were up to 97.2 and 98.4%, respectively. THP-1 cellular uptake of UVI-DENV present in the DNV was higher than soluble UVI-DENV alone. DNV stimulation of immature dendritic cells (iDCs) resulted in a significantly higher expression of DCs maturation markers (CD80, CD86 and HLA-DR) and induction of various cytokine and chemokine productions than in UVI-DENV-treated iDCs, suggesting a potential use of BCG- CS-NPs as adjuvant and delivery system for dengue vaccines.en_US
dc.rightsMahidol Universityen_US
dc.titleImmunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cellsen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.